Wen‐Jen Hwu

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Omid Hamid, Caroline Robert, Adil Daud et al. · Annals of Oncology · 2019 · 944 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prognostic factors for survival in melanoma patients with brain metastases

Michael A. Davies, Ping Liu, Susan McIntyre et al. · Cancer · 2010 · 548 citations

Medicine, Clinical Sciences, Oncology +7

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Laszlo Radvanyi, Chantale Bernatchez, Minying Zhang et al. · Clinical Cancer Research · 2012 · 433 citations · Full text

Medicine, Immunology, Oncology +17

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial

Rodabe N. Amaria, Peter A. Prieto, Michael T. Tetzlaff et al. · The Lancet Oncology · 2018 · 290 citations

Medicine, Oncology, Surgery +14

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature.

Antoni Ribas, Caroline Robert, F. Stephen Hodi et al. · Journal of Clinical Oncology · 2015 · 199 citations

Life Sciences, Immunology, Oncology +17